Clearmind Medicine Inc. Cash Flows From Used In Financing Activities
Clearmind Medicine Inc. (CMND) reported Cash Flows From Used In Financing Activities of $7.42 million for the 3-month period ending 2026-01-31, per its 6-K filed 2026-03-12.
Financial Statements › Cash Flow › Financing Activities
ifrs-full:CashFlowsFromUsedInFinancingActivities · last filed 2026-03-12
- Clearmind Medicine Inc. cash flows from used in financing activities for the quarter ending 2023-01-31 was 8.45M CAD.
CAD
| Period end | Cash Flows From Used In Financing Activities 3 month | Cash Flows From Used In Financing Activities 12 month |
|---|---|---|
| 2023-01-31 | 8.45M CAD 6-K · filed 2023-03-17 | |
| 2022-10-31 | 698.40K CAD 20-F · filed 2023-02-06 | |
| 2021-10-31 | 7.36M CAD 20-F · filed 2023-02-06 | |
| 2020-10-31 | 598.70K CAD 20-F · filed 2023-02-06 |
USD
| Period end | Cash Flows From Used In Financing Activities 3 month | Cash Flows From Used In Financing Activities 6 month | Cash Flows From Used In Financing Activities 9 month | Cash Flows From Used In Financing Activities 12 month |
|---|---|---|---|---|
| 2026-01-31 | $7.42M 6-K · filed 2026-03-12 | $9.66M derived: sum of 2 quarters · filed 2026-03-12 | $9.65M derived: sum of 3 quarters · filed 2026-03-12 | $9.63M derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-10-31 | $2.24M derived: 20-F 12 month − 6-K 9 month · filed 2026-01-20 | $2.23M derived: sum of 2 quarters · filed 2026-01-20 | $2.22M derived: sum of 3 quarters · filed 2026-01-20 | $2.62M 20-F · filed 2026-01-20 |
| 2025-07-31 | -$10.81K derived: 6-K 9 month − 6-K 6 month · filed 2025-09-11 | -$21.11K derived: sum of 2 quarters · filed 2025-09-11 | $383.70K 6-K · filed 2025-09-11 | $706.91K derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-04-30 | -$10.30K derived: 6-K 6 month − 6-K 3 month · filed 2025-06-12 | $394.51K 6-K · filed 2025-06-12 | $717.72K derived: sum of 3 quarters · filed 2026-03-12 | $1.19M derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-01-31 | $404.81K 6-K · filed 2026-03-12 | $728.02K derived: sum of 2 quarters · filed 2026-03-12 | $1.20M derived: sum of 3 quarters · filed 2026-03-12 | $1.34M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-10-31 | $323.20K derived: 20-F 12 month − 6-K 9 month · filed 2026-01-20 | $792.74K derived: sum of 2 quarters · filed 2026-01-20 | $937.87K derived: sum of 3 quarters · filed 2026-01-20 | $6.25M 20-F · filed 2026-01-20 |
| 2024-07-31 | $469.54K derived: 6-K 9 month − 6-K 6 month · filed 2025-09-11 | $614.67K derived: sum of 2 quarters · filed 2025-09-11 | $5.93M 6-K · filed 2025-09-11 | $8.34M derived: sum of 4 quarters · filed 2026-01-20 |
| 2024-04-30 | $145.13K derived: 6-K 6 month − 6-K 3 month · filed 2025-06-12 | $5.46M 6-K · filed 2025-06-12 | $7.87M derived: sum of 3 quarters · filed 2026-01-20 | $7.84M derived: sum of 4 quarters · filed 2026-01-20 |
| 2024-01-31 | $5.32M 6-K · filed 2025-03-13 | $7.72M derived: sum of 2 quarters · filed 2026-01-20 | $7.69M derived: sum of 3 quarters · filed 2026-01-20 | $10.63M derived: sum of 4 quarters · filed 2026-01-20 |
| 2023-10-31 | $2.41M derived: 20-F 12 month − 6-K 9 month · filed 2026-01-20 | $2.37M derived: sum of 2 quarters · filed 2026-01-20 | $5.32M derived: sum of 3 quarters · filed 2026-01-20 | $11.66M 20-F · filed 2026-01-20 |
| 2023-07-31 | -$31.69K derived: 6-K 9 month − 6-K 6 month · filed 2024-09-16 | $2.91M derived: sum of 2 quarters · filed 2024-09-16 | $9.26M 6-K · filed 2024-09-16 | |
| 2023-04-30 | $2.94M derived: 6-K 6 month − 6-K 3 month · filed 2024-06-13 | $9.29M 6-K · filed 2024-06-13 | ||
| 2023-01-31 | $6.35M 6-K · filed 2024-03-19 | |||
| 2022-10-31 | $511.69K 20-F · filed 2025-01-22 | |||
| 2022-04-30 | $629.01K 6-K · filed 2023-06-14 | |||
| 2021-10-31 | $5.39M 20-F/A · filed 2024-03-18 |